Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis

被引：0

作者：

Simpson, Eric ^{[1
]}

Boguniewicz, Mark ^{[2
,3
]}

Eichenfield, Lawrence ^{[4
]}

Gonzales, Mercedes E. ^{[5
]}

Hebert, Adelaide A. ^{[6
]}

Prajapati, Vimal H. ^{[7
,8
]}

Gooderham, Melinda ^{[9
,10
]}

Krupa, David ^{[11
]}

Chu, David H. ^{[11
]}

Higham, Robert C. ^{[11
]}

Berk, David R. ^{[11
]}

机构：

[1] Oregon Hlth & Sci Univ, Portland, OR USA

[2] Natl Jewish Hlth, Denver, CO USA

[3] Univ Colorado, Sch Med, Aurora, CO USA

[4] Univ Calif San Diego, Radys Childrens Hosp San Diego, San Diego, CA USA

[5] Pediat Skin Res LLC, Miami, FL USA

[6] UT Hlth, McGovern Med Sch, Houston, TX USA

[7] Skin Hlth Wellness Ctr, Dermatol Res Inst & Prob Med Res, Calgary, AB, Canada

[8] Univ Calgary, Calgary, AB, Canada

[9] SKiN Ctr Dermatol, Prob Med Res, Peterborough, ON, Canada

[10] Queens Univ, Peterborough, ON, Canada

[11] Arcutis Biotherapeut Inc, Westlake Village, CA USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷

关键词：

atopic dermatitis; efficacy; patient-reported outcomes; roflumilast cream; safety;

D O I：

10.1093/bjd/ljae266.022

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

641

引用

页数：1

共 50 条

[11] Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III StudiesRuxolitinib Cream: Phase III Patient-Reported Outcomes of Adolescents/Adults with Atopic DermatitisE. L. Simpson et al.
Eric L. Simpson
Matthias Augustin
Diamant Thaçi
Laurent Misery
April W. Armstrong
Andrew Blauvelt
Kim A. Papp
Jacek C. Szepietowski
Mark Boguniewicz
Shawn G. Kwatra
Howard Kallender
Daniel Sturm
Haobo Ren
Leon Kircik
American Journal of Clinical Dermatology, 2025, 26 (1) : 121 - 137
[12] Long-term safety and efficacy of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis: a 52-week, phase 3, open-label extension trial
Simpson, Eric L.
Eichenfield, Lawrence F.
Papp, Kim A.
Forman, Seth
Hebert, Adelaide A.
Gonzalez, Mercedes E.
Gooderham, Melinda
Hong, H. Chih-ho
Prajapati, Vimal H.
Guttman, Emma
Silverberg, Jonathan
Seal, Melissa
Krupa, David
Burnett, Patrick
Synder, Scott
Chu, David H.
Higham, Robert C.
Berk, David R.
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 20 - 20
[13] Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
Simpson, Eric L.
Prajapati, Vimal H.
Leshem, Yael A.
Chovatiya, Raj
de Bruin-Weller, Marjolein S.
Staender, Sonja
Pink, Andrew E.
Calimlim, Brian M.
Lee, Wan-Ju
Teixeira, Henrique
Ladizinski, Barry
Hu, Xiaofei
Yang, Yang
Liu, Yingyi
Liu, Meng
Grada, Ayman
Platt, Andrew M.
Silverberg, Jonathan I.
DERMATOLOGY AND THERAPY, 2024, 14 (05) : 1127 - 1144
[14] Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis
Thyssen, J. P.
Yosipovitch, G.
Paul, C.
Kwatra, S. G.
Chu, C. Y.
DiBonaventura, M.
Feeney, C.
Zhang, F.
Myers, D.
Rojo, R.
Valdez, H.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (03) : 434 - 443
[15] Dupilumab Improves Patient-Reported Outcomes (PROs) in a Phase 2 Study in Adults with Moderate-to-Severe Atopic Dermatitis
Simpson, Eric
Worm, Margitta
Soong, Weily
Blauvelt, Andrew
Eckert, Laurent
Wu, Richard
Ardeleanu, Marius
Graham, Neil
Pirozzi, Gianluca
Sutherland, E. Rand
Mastey, Vera
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB167 - AB167
[16] Tapinarof cream 1% once daily for plaque psoriasis: Patient-reported outcomes from two pivotal phase 3 trials
Bissonnette, Robert
Strober, Bruce
Lebwohl, Mark
Bagel, Jerry
Del Rosso, James
Merola, Joseph F.
Bhatia, Neal
Yamauchi, Paul
Brown, Philip M.
Rubenstein, David S.
Tallman, Anna M.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB71 - AB71
[17] Effects of ruxolitinib cream on patient-reported quality of life in atopic dermatitis: 52-week pooled results from two phase III studies
Simpson, Eric L.
Silverberg, Jonathan I.
Armstrong, April W.
Fuxench, Zelma C. Chiesa
Venturanza, May E.
Kallender, Howard
Gao, Jessy
Kircik, Leon
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E122 - E123
[18] Achieving a deep response on patient-reported outcomes with upadacitinib in patients with moderate to severe atopic dermatitis: Results from three phase 3 trials
Chovatiya, Raj
Schuttelaar, Marie-Louise
Calimlim, Brian
Liu, Yingyi
Takemoto, Shunya
Staender, Sonja
CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 1017 - 1018
[19] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials
Tofte, Susan J.
Papp, Kim
Sadick, Neil
Bohnert, Krista
Simpson, Eric
Thaci, Diamant
Bieber, Thomas
Blauvelt, Andrew
Sofen, Howard
Gooderham, Melinda
Chen, Zhen
Gadkari, Abhijit
Eckert, Laurent
Graham, Neil M. H.
Pirozzi, Gianluca
Ardeleanu, Marius
JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 (09): : 529 - 541
[20] Tapinarof cream 1% once daily: significant efficacy in the treatment of atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age
Silverberg, Jonathan, I
Eichenfield, Lawrence F.
Hebert, Adelaide A.
Simpson, Eric
Gold, Linda Stein
Bissonnette, Robert
Papp, Kim A.
Browning, John
Kwong, Pearl
Korman, Neil J.
Brown, Philip M.
Rubenstein, David S.
Piscitelli, Stephen C.
Somerville, Matthew C.
Tallman, Anna M.
Kircik, Leon
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II17 - II18

← 1 2 3 4 5 →